These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 31820485)

  • 21. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
    Remitz A; Harper J; Rustin M; Goldschmidt WF; Palatsi R; van der Valk PG; Sharpe G; Smith CH; Dobozy A; Turjanmaa K;
    Acta Derm Venereol; 2007; 87(1):54-61. PubMed ID: 17225017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
    Tom WL; Van Syoc M; Chanda S; Zane LT
    Pediatr Dermatol; 2016; 33(2):150-9. PubMed ID: 26777394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S; Ortonne JP; Sand C; Cambazard F; Bieber T; Fölster-Holst R; Vena G; Bos JD; Fabbri P; Groenhoej Larsen C;
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2024 Dec; 35(1):2344591. PubMed ID: 38653561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
    Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
    Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
    Murrell DF; Gebauer K; Spelman L; Zane LT
    J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
    Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
    Zhang L; Wang L; Jiang X
    Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.
    Saeki H; Ohya Y; Baba N; Imamura T; Yokota D; Tsubouchi H
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2443-2455. PubMed ID: 39075274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
    Zhang L; Du D; Wang L; Guo L; Jiang X
    J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
    Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
    JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK inhibitors in the treatment of atopic dermatitis.
    Chovatiya R; Paller AS
    J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis.
    Cheer SM; Plosker GL
    Am J Clin Dermatol; 2001; 2(6):389-406. PubMed ID: 11770393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
    Kubota Y; Yoneda K; Nakai K; Katsuura J; Moriue T; Matsuoka Y; Miyamoto I; Ohya Y
    J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group.
    Reitamo S; Wollenberg A; Schöpf E; Perrot JL; Marks R; Ruzicka T; Christophers E; Kapp A; Lahfa M; Rubins A; Jablonska S; Rustin M
    Arch Dermatol; 2000 Aug; 136(8):999-1006. PubMed ID: 10926735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.